Ignite Creation Date:
2025-12-24 @ 1:59 PM
Ignite Modification Date:
2026-01-08 @ 9:52 AM
Study NCT ID:
NCT03672695
Status:
COMPLETED
Last Update Posted:
2024-02-05
First Post:
2018-09-04
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D015470', 'term': 'Leukemia, Myeloid, Acute'}], 'ancestors': [{'id': 'D007951', 'term': 'Leukemia, Myeloid'}, {'id': 'D007938', 'term': 'Leukemia'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D006402', 'term': 'Hematologic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C579720', 'term': 'venetoclax'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NON_RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SEQUENTIAL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 37}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2018-11-28', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-02', 'completionDateStruct': {'date': '2023-05-30', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-02-01', 'studyFirstSubmitDate': '2018-09-04', 'studyFirstSubmitQcDate': '2018-09-13', 'lastUpdatePostDateStruct': {'date': '2024-02-05', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2018-09-14', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-11-12', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence of Dose Limiting Toxicity (DLTs)', 'timeFrame': 'At the end of cycle 1 (each cycle is 21 or 28 days).'}, {'measure': 'Incidence and severity of AEs', 'timeFrame': 'Through study completion, an average of 6 months.'}, {'measure': 'Incidence and severity of SAEs', 'timeFrame': 'Through study completion, an average of 6 months.'}, {'measure': 'Number of participants with dose interruptions "will be measured and reported in the Outcome Measure results data table.', 'timeFrame': 'Through study completion, an average of 6 months.'}, {'measure': 'Number of participants with dose reductions "will be measured and reported in the Outcome Measure results data table.', 'timeFrame': 'Through study completion, an average of 6 months.'}, {'measure': 'Dose intensity', 'timeFrame': 'Through study completion, an average of 6 months.'}], 'secondaryOutcomes': [{'measure': 'Anti-leukemic activity', 'timeFrame': 'Through study completion, an average of 6 months.', 'description': 'Using blood, bone marrow aspirate and medullary biopsy if available according to ELN 2017 criteria'}, {'measure': 'Pharmacokinetic profile of S64315 administered in combination with Venetoclax in plasma: Area Under the Curve (AUC)', 'timeFrame': 'From Day 1 of cycle 1 to the end of cycle 2 (each cycle is 21 or 28 days).'}, {'measure': 'Pharmacokinetic profile of S64315 administered in combination with Venetoclax in plasma: Concentration at the end of infusion (Cinf)', 'timeFrame': 'From Day 1 of cycle 1 to the end of cycle 2 (each cycle is 21 or 28 days).'}, {'measure': 'Pharmacokinetic profile of S64315 administered in combination with Venetoclax in plasma: terminal half-life (t½z)', 'timeFrame': 'From Day 1 of cycle 1 to the end of cycle 2 (each cycle is 21 or 28 days).'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Acute Myeloid Leukaemia']}, 'referencesModule': {'availIpds': [{'url': 'https://clinicaltrials.servier.com/', 'type': 'Individual Participant Data Set'}, {'url': 'https://clinicaltrials.servier.com/', 'type': 'Study Protocol'}, {'url': 'https://clinicaltrials.servier.com/', 'type': 'Statistical Analysis Plan'}, {'url': 'https://clinicaltrials.servier.com/', 'type': 'Informed Consent Form'}, {'url': 'https://clinicaltrials.servier.com/', 'type': 'Clinical Study Report'}], 'seeAlsoLinks': [{'url': 'https://clinicaltrials.servier.com/', 'label': 'Find Results on Servier Clinical Trial Data website'}, {'url': 'https://clinicaltrials.servier.com/trial/an-international-phase-ib-multicentre-study-to-characterize-the-safety-and-tolerability-of-intravenously-administered-s64315-a-selective-mcl-1-inhibitor-in-combination-with-orally-administered-veneto/', 'label': 'Link to Lay Summary and Results Summary'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to determine the safety profile, tolerability and the Recommended Phase 2 Dose of the combination S64315 with venetoclax in patients with Acute Myeloid Leukaemia.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Male or female aged ≥ 18 years;\n2. Patients with cytologically confirmed and documented de novo, secondary or therapy-related AML as defined by World Health Organization (WHO) 2016 classification (Arber, 2016), excluding acute promyelocytic leukaemia (APL, French-American British M3 classification):\n\n * With relapsed or refractory disease without established alternative therapy or\n * Secondary to MDS treated at least by hypomethylating agent and without established alternative therapy or\n * ≥ 65 years not previously treated for AML and who are not candidates for intensive chemotherapy nor candidates for established alternative therapy\n3. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2\n4. Able to comply with study procedures\n5. Adequate renal function within 7 days before the inclusion of the patient defined as:\n\n • Serum creatinine ≤ 1.5 x ULN (upper normal limit) or calculated creatinine clearance (determined by MDRD) \\> 50 mL/min/1.73m2\n6. Adequate hepatic function within 7 days before the inclusion of the patient defined as:\n\n * AST and ALT ≤ 1.5 x ULN\n * Total serum bilirubin level ≤ 1.5 x ULN, except for patients with known Gilbert's syndrome, who are excluded if total bilirubin \\> 3.0 x ULN or direct bilirubin \\> 1.5 x ULN\n\nExclusion Criteria:\n\n1. Participant already enrolled and treated in the study\n2. Pregnancy, breastfeeding or possibility of becoming pregnant during the study\n3. Participation in another interventional study requiring investigational treatment intake at the same time or within 2 weeks or at least 5 halflives (whichever is longer) prior to first dose of IMP (participation in non-interventional registries or epidemiological studies is allowed). In case of biologic agents with a long half life such as CART cells, immune checkpoint antibodies, bispecific antibodies a flat wash-out of 28 days will be acceptable\n4. Presence of ≥ CTCAE Grade 2 toxicity (except alopecia of any grade) due to prior cancer therapy, according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCICTCAE, version 4.03).\n5. Known carriers of HIV antibodies\n6. Known history of significant liver disease\n7. Uncontrolled hepatitis B or C infection\n8. Known active acute or chronic pancreatitis\n9. History of myocardial infarction (MI), unstable angina pectoris, coronary artery bypass graft (CABG) within 6 months prior to starting study treatment\n10. Any factors that could increase the risk of QTc prolongation or risk of arrhythmic events."}, 'identificationModule': {'nctId': 'NCT03672695', 'briefTitle': 'Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.', 'organization': {'class': 'INDUSTRY', 'fullName': 'Servier'}, 'officialTitle': 'An International Phase Ib Multicentre Study to Characterize the Safety and Tolerability of Intravenously Administered S64315, a Selective Mcl-1 Inhibitor, in Combination With Orally Administered Venetoclax, a Selective Bcl-2 Inhibitor in Patients With Acute Myeloid Leukaemia (AML).', 'orgStudyIdInfo': {'id': 'CL1-64315-002'}, 'secondaryIdInfos': [{'id': '2018-001809-88', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Initial Schedule - S64315 low dose and venetoclax high dose administered in combination', 'interventionNames': ['Combination Product: S 64315 (also referred as MIK665) and venetoclax']}, {'type': 'EXPERIMENTAL', 'label': 'Initial Schedule - S64315 medium dose and venetoclax low dose administered in combination', 'interventionNames': ['Combination Product: S 64315 (also referred as MIK665) and venetoclax']}, {'type': 'EXPERIMENTAL', 'label': 'Initial Schedule - S64315 medium dose and venetoclax medium dose administered in combination', 'interventionNames': ['Combination Product: S 64315 (also referred as MIK665) and venetoclax']}, {'type': 'EXPERIMENTAL', 'label': 'Initial Schedule - S64315 medium dose and venetoclax high dose administered in combination', 'interventionNames': ['Combination Product: S 64315 (also referred as MIK665) and venetoclax']}, {'type': 'EXPERIMENTAL', 'label': 'Initial Schedule - S64315 high dose and venetoclax medium dose administered in combination', 'interventionNames': ['Combination Product: S 64315 (also referred as MIK665) and venetoclax']}, {'type': 'EXPERIMENTAL', 'label': 'Alternative Schedule - Venetoclax medium dose administered with no S64315', 'interventionNames': ['Combination Product: S 64315 (also referred as MIK665) and venetoclax']}, {'type': 'EXPERIMENTAL', 'label': 'Alternative Schedule - S64315 medium dose and venetoclax medium dose administered in combination', 'interventionNames': ['Combination Product: S 64315 (also referred as MIK665) and venetoclax']}, {'type': 'EXPERIMENTAL', 'label': 'Alternative Schedule - S64315 high dose and venetoclax low dose administered in combination', 'interventionNames': ['Combination Product: S 64315 (also referred as MIK665) and venetoclax']}], 'interventions': [{'name': 'S 64315 (also referred as MIK665) and venetoclax', 'type': 'COMBINATION_PRODUCT', 'description': 'The treatment combination period can only begin after the planned dose of venetoclax is reached. Depending on the administration dosing schedule, the combination treatment at the planned doses may be preceded by a 2-week Lead-In Dose period of S64315 (fixed dose) during which the patient continues to receive venetoclax daily. Once the planned dose of both drugs is reached the schedule will be a 21-day cycle with a weekly regimen for S64315 and a daily regimen for venetoclax.\n\nS64315 should be administered 2 to 4 hours after venetoclax intake, via IV infusion. The dose escalation will start at 50 mg once a week and doses up to 250 mg once a week might be explored.\n\nVenetoclax will be administered orally once a day. The dose escalation will start at 100 mg daily and doses up to 600 mg daily might be explored. Venetoclax must be taken with a meal (ideally during breakfast) in order to avoid reduced efficacy.', 'armGroupLabels': ['Alternative Schedule - S64315 high dose and venetoclax low dose administered in combination', 'Alternative Schedule - S64315 medium dose and venetoclax medium dose administered in combination', 'Alternative Schedule - Venetoclax medium dose administered with no S64315', 'Initial Schedule - S64315 high dose and venetoclax medium dose administered in combination', 'Initial Schedule - S64315 low dose and venetoclax high dose administered in combination', 'Initial Schedule - S64315 medium dose and venetoclax high dose administered in combination', 'Initial Schedule - S64315 medium dose and venetoclax low dose administered in combination', 'Initial Schedule - S64315 medium dose and venetoclax medium dose administered in combination']}]}, 'contactsLocationsModule': {'locations': [{'zip': '06511', 'city': 'New Haven', 'state': 'Connecticut', 'country': 'United States', 'facility': 'Smilow Cancer Hospital at Yale', 'geoPoint': {'lat': 41.30815, 'lon': -72.92816}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'The University of Texas MD Anderson Cancer Center, Houston, TX', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'city': 'Melbourne', 'country': 'Australia', 'facility': 'Peter MacCallum cancer centrer', 'geoPoint': {'lat': -37.814, 'lon': 144.96332}}, {'city': 'Victoria Park', 'country': 'Australia', 'facility': 'The Alfred Hospital Department of Haematology', 'geoPoint': {'lat': -31.97619, 'lon': 115.90525}}, {'city': 'Marseille', 'country': 'France', 'facility': 'Institut Paoli-Calmettes', 'geoPoint': {'lat': 43.29695, 'lon': 5.38107}}, {'city': 'Paris', 'country': 'France', 'facility': 'Hopital Saint-Antoine', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'city': 'Toulouse', 'country': 'France', 'facility': 'Institut Universitaire du Cancer Toulouse - Oncopole', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}], 'overallOfficials': [{'name': 'Andrew WEI', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'The Alfred Hospital, Melbourne, Victoria'}]}, 'ipdSharingStatementModule': {'url': 'https://clinicaltrials.servier.com/', 'infoTypes': ['STUDY_PROTOCOL', 'SAP', 'ICF', 'CSR'], 'timeFrame': 'After Marketing Authorisation in EEA or US if the study is used for the approval.', 'ipdSharing': 'YES', 'description': 'Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.\n\nAccess can be requested for all interventional clinical studies:\n\n* used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).\n* where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.\n\nIn addition, access can be requested for all interventional clinical studies in patients:\n\n* sponsored by Servier\n* with a first patient enrolled as of 1 January 2004 onwards\n* for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.', 'accessCriteria': 'Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Institut de Recherches Internationales Servier', 'class': 'OTHER'}, 'collaborators': [{'name': 'ADIR, a Servier Group company', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}